ASCO 2020 | DS-8201 + pembro in patients HER2+ breast and NSCLC

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses data from a phase II study which evaluated the use of trastuzumab deruxtecan in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).